Details werden geladen...
Cenna Biosciences Inc.: Cenna Biosciences Receives FDA Clearance to Begin Phase 1a/1b Clinical Trial of 8M2D, a First-in-Class Peptide Designed to Stop the Production of Amyloid in Alzheimer's Disease
Clearance advances 8M2D, designed to inhibit β-amyloid production rather than clear plaque after it forms; first participant expected to be dosed in late 2026 LA JOLLA, CA / ACCESS Newswire / June 17,
Ähnliche Seiten
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/ibio-becomes-a-clinical-stage-company-with-first-participant-dosed-in-phase-1-clinical-trial-of-ibio-600-in-adults-with-obesity/2356645
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer | The Manila Times
https://www.manilatimes.net/2026/06/16/tmt-newswire/globenewswire/novabridge-biosciences-receives-fda-fast-track-designation-for-givastomig-in-first-line-her2-negative-metastatic-gastric-cancer/2366382Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1 | The Manila Times
https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/ambros-therapeutics-announces-first-patient-dosed-in-pivotal-crps-rise-phase-3-clinical-trial-of-neridronate-in-patients-with-complex-regional-pain-syndrome-type-1/2360811